Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Shares Outstanding (Weighted Average) (2016 - 2025)

iBio (IBIO) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $76.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 732.57% to $76.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.0 million through Dec 2025, up 732.57% year-over-year, with the annual reading at $10.5 million for FY2025, 174.05% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $76.0 million at iBio, up from $53.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $188.5 million in Q1 2021, with the low at $466000.0 in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $20.9 million, with a median of $8.7 million recorded in 2021.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 235760.96% in 2021, then plummeted 95.37% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $8.7 million in 2021, then plummeted by 94.65% to $466000.0 in 2022, then skyrocketed by 227.25% to $1.5 million in 2023, then skyrocketed by 498.82% to $9.1 million in 2024, then skyrocketed by 732.57% to $76.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $76.0 million, $53.0 million, and $10.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.